Fund 3
Vesalius Biocapital III

This fund, launched in May 2017 and finally closed in May 2019, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

€120 million of commitments secured

The fund secured over €120 million of commitments; final closing took place in May 2019.



News for Vesalius Biocapital Fund 3

Memo Therapeutics: CEO Erik van den Berg
read more
Memo Therapeutics: CHF 25 Million Financing
read more
Rejuvenate Biomed: Positive results
read more